Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology
-
Ann. Allergy Asthma Immunol. · Feb 2021
Randomized Controlled Trial Multicenter StudyTezepelumab improves patient-reported outcomes in patients with severe, uncontrolled asthma in PATHWAY.
Patients with severe, uncontrolled asthma experience frequent exacerbations and hospitalization, leading to poor health-related quality of life. In the phase 2b PATHWAY study (NCT02054130), tezepelumab reduced exacerbations by up to 71% and improved lung function, asthma control, and health-related quality of life vs placebo. ⋯ Tezepelumab treatment improved PROs vs placebo, as indicated by the higher proportion of ACQ-6 and AQLQ(S)+12 responders and improvements in symptom severity in the tezepelumab dose groups. These data further support the benefits of tezepelumab in patients with severe, uncontrolled asthma.
-
Ann. Allergy Asthma Immunol. · May 2018
Randomized Controlled Trial Multicenter StudyBenralizumab efficacy by atopy status and serum immunoglobulin E for patients with severe, uncontrolled asthma.
Patients with severe asthma can have eosinophilic inflammation and/or allergen sensitization. Benralizumab is an anti-eosinophilic monoclonal antibody indicated for add-on maintenance treatment of patients with severe asthma aged 12 years and older, and with an eosinophilic phenotype. ⋯ Benralizumab treatment decreased exacerbations and improved lung function for patients with severe, uncontrolled eosinophilic asthma regardless of serum IgE concentrations and atopy status.
-
Ann. Allergy Asthma Immunol. · Dec 2015
Randomized Controlled Trial Multicenter Study Clinical TrialTimothy specific IgE levels are associated with efficacy and safety of timothy grass sublingual immunotherapy tablet.
Regional pollen allergen exposure differences may induce variable sensitization profiles that could affect allergen immunotherapy efficacy and safety. ⋯ Sensitization profiles varied by region. Trends toward higher efficacy and increased TRAE incidence in subjects with higher pretreatment Phl p IgE levels were observed.
-
Ann. Allergy Asthma Immunol. · Jun 2015
Multicenter Study Observational StudyFactors associated with hospital admission in hereditary angioedema attacks: a multicenter prospective study.
Acute attacks of hereditary angioedema are characterized by recurrent localized edema. These attacks can be life threatening and are associated with substantial morbidity and mortality. ⋯ Most patients attended the emergency department because they were running out of medication and did not know that emergency treatment could be self-administered. Risk factors associated with hospital admission were laryngeal and facial involvement, whereas self-injection of icatibant was associated with a return home.
-
Ann. Allergy Asthma Immunol. · Dec 2014
Letter Randomized Controlled Trial Multicenter StudySublingual immunotherapy in mite-sensitized children with atopic dermatitis: a randomized, open, parallel-group study.